RecruitingPhase 2NCT05817214
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Studying Isolated femoral agenesis/hypoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhongnan Hospital
- Principal Investigator
- Hui Qiu, Ph.D.Wuhan University
- Intervention
- Cadonilimab(drug)
- Enrollment
- 35 target
- Eligibility
- 18-75 years · FEMALE
- Timeline
- 2023 – 2027
Study locations (1)
- Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Collaborators
Akeso Biopharma Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05817214 on ClinicalTrials.govOther trials for Isolated femoral agenesis/hypoplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07539792Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Transsphenoidal Surgery: A Prospective, Randomized, Controlled StudyNanfang Hospital, Southern Medical University
- ACTIVE NOT RECRUITINGNCT07151794G8, CARG, Frailty, and Nutritional Markers in Predicting ChemotoxicityÇanakkale Onsekiz Mart University
- RECRUITINGEARLY PHASE1NCT06216938RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node MetastasisYana Najjar
- RECRUITINGNCT06164483Auditory Functions in Patients With Multiple SclerosisUniversity of Catania
- ENROLLING BY INVITATIONNANCT04498026Adherus™ Dural Sealant in Spinal ProceduresStryker Craniomaxillofacial
- RECRUITINGNANCT04099823MR Evaluation of Cerebrospinal Fluid (CSF) DynamicsMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT03866525OH2 Oncolytic Viral Therapy in Solid TumorsBinhui Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT04386967OH2 Injection in Solid TumorsBinhui Biopharmaceutical Co., Ltd.